The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedAlleviating anemia and thrombocytopenia in myelofibrosis patients.Managing patients with myelofibrosis and low platelet counts.Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.Prognosis of Primary Myelofibrosis in the Genomic EraEpidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation.Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.SOHO State-of-the-Art Update and Next Questions: MPN.Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.
P2860
Q26738514-5601E8BF-5335-49CB-AA06-D28561CBAA1CQ33430113-F5CFFF9F-34CA-4A92-8426-FED8A354C408Q33432406-4B68CBCA-6C1B-4107-82B4-BEA57F794E11Q33442613-6D3A4061-77D0-4845-9307-612A9AE07CABQ37555790-91D7B47C-AE5B-41A1-A9DA-3482CA91474AQ38683077-8A240E75-4917-4BFA-BEE3-F1E99A8B3EC2Q38684435-BDD2F4C5-8C21-400C-8A08-393F063EDEADQ38691019-1D254A8F-5DF4-4AEA-AA0A-7576C7F80DF6Q38926804-CFAD9A3A-126F-4D5D-B7FE-9FB697260831Q39869997-D3F09A53-D32E-4A29-BE46-0A6BD339701CQ40086569-9F5C349E-1BDE-42AF-AFB2-D9EC344069F2Q41360015-F7DE86E5-16C4-4AB6-9827-C50173B1A94CQ48144615-5B834476-A273-441A-ADD8-F6EEEB9479FDQ48735434-FDAB7B3C-5B42-4AB0-A6F7-1E72E7F144B9Q49580473-5847A06E-4449-4319-9B45-F0A1E4B7C72EQ49951911-17B3279A-03A9-4A8F-A1F8-54BF5C540FAF
P2860
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The International Prognostic S ...... lycythemia vera myelofibrosis.
@en
The International Prognostic S ...... lycythemia vera myelofibrosis.
@nl
type
label
The International Prognostic S ...... lycythemia vera myelofibrosis.
@en
The International Prognostic S ...... lycythemia vera myelofibrosis.
@nl
prefLabel
The International Prognostic S ...... lycythemia vera myelofibrosis.
@en
The International Prognostic S ...... lycythemia vera myelofibrosis.
@nl
P2093
P2860
P50
P1433
P1476
The International Prognostic S ...... lycythemia vera myelofibrosis.
@en
P2093
Alberto Alvarez-Larrán
Ana Kerguelen
Arturo Pereira
Blanca Xicoy
Carles Besses
Concepción Boqué
Elisa Arbelo
Elisa Luño
Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas
Jesús Martínez
P2860
P356
10.3324/HAEMATOL.2013.101733
P577
2014-01-31T00:00:00Z